Short-term and medium-term clinical outcomes of quinolone-resistant Campylobacter infection

Clinical Infectious Diseases

Volumn 48, Issue 11, 2009, Pages 1500-1506

  Evans, Meirion R ^a,b   Northey, Gemma ^a   Sarvotham, Tinnu S ^a   Rigby, Christine J ^a   Hopkins, A Lynne ^a   Thomas, Daniel Rh ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b PUBLIC HEALTH WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; DIPHENOXYLATE; ERYTHROMYCIN; LOPERAMIDE; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; CAMPYLOBACTER; CAMPYLOBACTERIOSIS; CHILD; COMPARATIVE STUDY; CONSULTATION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DISK DIFFUSION; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; INFANT; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE REGRESSION; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TELEPHONE; TIME SERIES ANALYSIS; UNITED KINGDOM; ANTIBIOTIC RESISTANCE; CASE CONTROL STUDY; DRUG EFFECT; GASTROENTERITIS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CAMPYLOBACTER; CAMPYLOBACTER INFECTIONS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; GASTROENTERITIS; HUMANS; INFANT; INTERVIEWS AS TOPIC; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; QUINOLONES; TREATMENT OUTCOME; WALES; YOUNG ADULT;

EID: 66949131416     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598932     Document Type: Article

References (24)

1. Health Protection Agency (HPA). Campylobacter spp: laboratory reports of faecal isolates reported to the HPA Centre for Infections, England and Wales 1986-2006. Available at: http://www.hpa.org.uk/ infections/topics-az/ campy/data-ew.htm. Accessed 28 August 2008.
2. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331-50.
3. Kist M. Impact and management of Campylobacter in human medicine-European perspective. Int J Infect Dis 2002;6(Suppl 3):3S44-8.
4. Pasternack MS. Impact and management of Campylobacter in human medicine-US perspective. Int J Infect Dis 2002;6(Suppl 3):3S37-43.
5. Oldfield EC III, Wallace MR. The role of antibiotics in the treatment of infectious diarrhea. Gastroenterol Clin North Am 2001;30:817-36.
6. Ternhag A, Asikainen T, Giesecke J, Ekdahl K. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis 2007; 44:696-70.
7. Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I.Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001; 7:24-34.
8. Moore JE, Barton MD, Blair IS, et al. The epidemiology of antibiotic resistance in Campylobacter. Microbes Infect 2006;8:1955-66.
9. Health Protection Agency. Antimicrobial resistance in England, Wales and Northern Ireland, 2006. London: Health Protection Agency, 2007.
10. Molbak K. Human health consequences of antimicrobial drug-resistant Salmonella and other foodborne pathogens. Clin Infect Dis 2005;41:1613-20.
11. Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Cam- pylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med 1999;340:1525-32.
12. Nelson JM, Smith KE, Vugia DJ, et al. Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. J Infect Dis 2004;190:1150-7.
13. Engberg J, Neimann J, Nielsen EM, Aarestrup FM, Fussing V. Quin- olone-resistant Campylobacter infections in Denmark: risk factors and clinical consequences. Emerg Infect Dis 2004; 10:1056-63.
14. Cox LA, Copeland D, Vaughn M. Ciprofloxacin resistance does not affect duration of domestically acquired campylobacteriosis. J Infect Dis 2005; 191:1565-6.
15. Wassenaar TM, Kist M, de Jon A. Re-analysis of the risks attributed to ciprofloxacin-resistant Campylobacter jejuni infections. Int J Anti- microb Agents 2007;30:195-201.
16. The Campylobacter Sentinel Surveillance Scheme Collaborators. Cip- rofloxacin resistance in Campylobacter jejuni: case-case analysis as a tool for elucidating risks at home and abroad. J Antimicrob Chemother 2002;50:561-8.
17. Helms M, Simonsen J, Olsen KP, Molbak K. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. J Infect Dis 2005; 191:1050-5.
18. King A. Recommendations for susceptibility test on fastidious organisms and those requiring special handling. J Antimicrob Chemother 2001;48(Suppl 1):77-80.
19. Silley P. Campylobacter and fluoroquinolones: a bias data set? Environ Microbiol 2003;5:219-30.
20. Shryock TR. Internationally recognized antimicrobial susceptibility testing methods and interpretive criteria: the case for conformity. J Infect Dis 2005; 192:2027-8.
21. McCarthy N, Giesecke J. Case-case comparisons to study causation of common infectious diseases. Int J Epidemiol 1999; 28:764-8.
22. Unicomb LE, Ferguson J, Stafford RJ, et al. Low-level fluoroquinolone resistance among Campylobacter jejuni isolates in Australia. Clin Infect Dis 2006;42:1368-74.
23. Travers K, Barza M. Morbidity of infections caused by anti-microbial resistant bacteria. Clin Infect Dis 2002; 34(Suppl 3):S131-4.
24. Ruiz-Palacios GM. The health burden of Campylobacter infection and the impact of antimicrobial resistance: playing chicken. Clin Infect Dis2007; 44:701-3.